These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 15640822)
1. Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial. Gupta S; Zhou P; Hassoun H; Kewalramani T; Reich L; Costello S; Drake L; Klimek V; Dhodapkar M; Teruya-Feldstein J; Hedvat C; Kalakonda N; Fleisher M; Filippa D; Qin J; Nimer SD; Comenzo RL Bone Marrow Transplant; 2005 Mar; 35(5):441-7. PubMed ID: 15640822 [TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
3. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature. Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563 [TBL] [Abstract][Full Text] [Related]
4. A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma. Cooling L; Hoffmann S; Herrst M; Muck C; Armelagos H; Davenport R Transfusion; 2010 Jan; 50(1):100-19. PubMed ID: 19719472 [TBL] [Abstract][Full Text] [Related]
5. Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma. Bilgrami S; Bona RD; Edwards RL; Li Z; Naqvi B; Shaikh A; Furlong F; Fox J; Clive J; Tutschka PJ Bone Marrow Transplant; 2001 Jul; 28(2):137-43. PubMed ID: 11509931 [TBL] [Abstract][Full Text] [Related]
6. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Lerro KA; Medoff E; Wu Y; Seropian SE; Snyder E; Krause D; Cooper DL Bone Marrow Transplant; 2003 Dec; 32(12):1113-7. PubMed ID: 14647264 [TBL] [Abstract][Full Text] [Related]
7. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Wuchter P; Ran D; Bruckner T; Schmitt T; Witzens-Harig M; Neben K; Goldschmidt H; Ho AD Biol Blood Marrow Transplant; 2010 Apr; 16(4):490-9. PubMed ID: 19925876 [TBL] [Abstract][Full Text] [Related]
8. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma. Huijgens PC; Dekker-Van Roessel HM; Jonkhoff AR; Admiraal GC; Zweegman S; Schuurhuis GJ; Ossenkoppele GJ Bone Marrow Transplant; 2001 May; 27(9):925-31. PubMed ID: 11436102 [TBL] [Abstract][Full Text] [Related]
9. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells. Hart C; Grassinger J; Andreesen R; Hennemann B Bone Marrow Transplant; 2009 Feb; 43(3):197-206. PubMed ID: 18806833 [TBL] [Abstract][Full Text] [Related]
10. Etoposide 1.0 g/m2 or 1.5 g/m2 combined with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells in patients with malignancy: efficacy and toxicity. Li B; Yang JL; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang S; Zhang CG Cytotherapy; 2009; 11(3):362-71. PubMed ID: 19037766 [TBL] [Abstract][Full Text] [Related]
11. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Gojo I; Guo C; Sarkodee-Adoo C; Meisenberg B; Fassas A; Rapoport AP; Cottler-Fox M; Heyman M; Takebe N; Tricot G Bone Marrow Transplant; 2004 Jul; 34(1):69-76. PubMed ID: 15133484 [TBL] [Abstract][Full Text] [Related]
12. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective. Bargetzi MJ; Passweg J; Baertschi E; Schoenenberger A; Gwerder C; Tichelli A; Burger J; Mingrone W; Herrmann R; Gratwohl A; Wernli M Bone Marrow Transplant; 2003 Jan; 31(2):99-103. PubMed ID: 12621490 [TBL] [Abstract][Full Text] [Related]
13. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome. Patriarca F; Damiani D; Fanin R; Grimaz S; Geromin A; Cerno M; Sperotto A; Silvestri F; Zaja F; Baccarani M Haematologica; 2000 Mar; 85(3):269-74. PubMed ID: 10702815 [TBL] [Abstract][Full Text] [Related]
14. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420 [TBL] [Abstract][Full Text] [Related]
15. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592 [TBL] [Abstract][Full Text] [Related]
16. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545 [TBL] [Abstract][Full Text] [Related]
17. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma. Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP Cytotherapy; 2008; 10(5):507-17. PubMed ID: 18608354 [TBL] [Abstract][Full Text] [Related]
18. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF. Callera F; Cavenaghi L; de Melo CM Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma. Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456 [TBL] [Abstract][Full Text] [Related]
20. Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma. Annunziata M; Celentano M; Pocali B; D'Amico MR; Palmieri S; Viola A; Copia C; Falco C; Del Vecchio L; Ferrara F Ann Hematol; 2006 Jun; 85(6):394-9. PubMed ID: 16538502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]